Krystal Biotech, Inc. (KRYS) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- Krystal Biotech, Inc. KRYS 316.58 −4.07%
- Madrigal Pharmaceuticals, Inc. MDGL 449.74 −2.19%
Krystal Biotech, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Krystal Biotech, Inc. and Madrigal Pharmaceuticals, Inc. are of similar size ($10.6B and $9.8B). Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Krystal Biotech, Inc. trades at 38.3×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 22.6%. Krystal Biotech, Inc. has the higher net margin (54.8% vs −25.3%) and the higher return on invested capital (24.1% vs −787.3%). Across the 17 metrics below, Krystal Biotech, Inc. leads on 14 and Madrigal Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | KRYS | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.64% | 91.48% | 65.16% |
| Operating margin | 44.89% | (25.13%) | 0.00% |
| Net margin | 54.82% | (25.32%) | 0.00% |
| Free cash flow margin | 58.52% | (16.07%) | 0.00% |
| Return on equity | 20.12% | (53.31%) | (56.36%) |
| Return on assets | 18.30% | (28.77%) | (48.04%) |
| Return on invested capital | 24.07% | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack